Anti-Tim-3/CD123 CAR T-cell therapy for resistant AML
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a special immune cell therapy (CAR T-cells) that targets two proteins on leukemia cells. It is for people whose AML has returned or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have acute myeloid leukemia (AML) that has come back or not improved with standard treatment.
- Your overall health is fairly good (able to do daily activities, with adequate liver, kidney, heart, and lung function).
- You do not have active infections, serious heart disease, or a history of certain brain or nervous system disorders.
- You are willing to use effective birth control for up to 2 years after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (called Allo-RevCAR01-T cells) for people with relapsed or hard-to-treat acute myeloid leukemia (AML) that has a marker called CD123. The treatment is given with a separate molecule that helps activate these cells to attack the leukemia. The goal is to see if this approach is safe and can help control the disease.
This trial tests a new type of CAR-T cell therapy that targets two proteins on leukemia cells (called CLL1 and CD33). The goal is to help people with acute myeloid leukemia that has relapsed or not responded to standard treatments.
This trial tests a new treatment that uses your own immune cells, modified in the lab to find and attack leukemia cells. It's for people with AML that has come back or hasn't responded to standard treatment, and it may be followed by a stem cell transplant to help prevent the cancer from returning.
This trial tests a new treatment made from your own immune cells (CAR-T cells) that are designed to find and kill leukemia cells that have the FLT3 protein. It is for people with acute myeloid leukemia (AML) that has not responded to standard therapy or has returned after treatment.
This trial tests an experimental treatment using your own immune cells (called CAR-T cells) that are specially designed to find and destroy leukemia cells that have a specific marker called CD123. It is for people with acute myeloid leukemia (AML) that has not responded to treatment or has returned, and who have limited other options.
This study tests a new treatment made from your own immune cells, engineered to find and attack AML cells. It is for patients whose leukemia has not responded to standard therapy or has come back after treatment, including after a stem cell transplant.
Hear when a new Acute Myeloid Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.